GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Price-to-Free-Cash-Flow

Albireo Pharma (FRA:BDQM) Price-to-Free-Cash-Flow : N/A (As of Jun. 09, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Price-to-Free-Cash-Flow?

As of today (2024-06-09), Albireo Pharma's share price is €41.41. Albireo Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2022 was €-5.62. Hence, Albireo Pharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Albireo Pharma's Price-to-Free-Cash-Flow or its related term are showing as below:

FRA:BDQM's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.545
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Albireo Pharma's Free Cash Flow per Share for the three months ended in Sep. 2022 was €-1.53. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-5.62.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -34.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -6.30% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 26.00% per year.

During the past 13 years, Albireo Pharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 48.70% per year. The lowest was -43.70% per year. And the median was 28.75% per year.


Albireo Pharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Albireo Pharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Price-to-Free-Cash-Flow Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Albireo Pharma's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Albireo Pharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albireo Pharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Price-to-Free-Cash-Flow falls into.



Albireo Pharma Price-to-Free-Cash-Flow Calculation

Albireo Pharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=41.41/-5.623
=N/A

Albireo Pharma's Share Price of today is €41.41.
Albireo Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.62.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Albireo Pharma  (FRA:BDQM) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Albireo Pharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (FRA:BDQM) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines